Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

FDA Expands Evolut Indication to Include Redo TAVI

News Daily News

FDA Expands Evolut Indications to Include Redo TAVI

Yael L. Maxwell

August 29, 2025

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Shelley Wood

April 24, 2019

News Industry News

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

April 23, 2019

News Daily News

FDA Approves Pea-Sized Occluder for Patent Ductus Arteriosus in Premature Babies

L.A. McKeown

January 14, 2019

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

L.A. McKeown

October 27, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

Advertisement

FDA Expands Evolut Indications to Include Redo TAVI

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Roughly 80% of ESC Guideline Writers Have Financial COIs

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Sapien 3 Valve Approved in Europe for Low-Risk Patients

FDA Expands TAVR Indication to Low-Risk Patients

FDA Approves Lotus Edge, Ushering Third Device Into US Market

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

FDA Approves Pea-Sized Occluder for Patent Ductus Arteriosus in Premature Babies

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content